Radboudumc and partners Spin-off companies ATRO Medical BV EU grant awarded to development of meniscus prosthesis

8 June 2022

The Dutch startup works on the first anatomical meniscus prostheses for patients with chronic knee pain. Their ground-breaking innovation continues to attract international attention, paving the way towards full-scale healthcare implementation.

The EIC Accelerator program is the most important instrument of the European Commission to support promising healthcare innovations. The program aims to develop and scale up game changing innovations. The EIC Accelerator grant provides access to an investment by the EIC Fund, coordinated by the European Commission and particularly used to bridge the funding gap between market entry and scale up.

The € 2.5 million grant will be spent on accelerating pre-clinical testing of the meniscus prostheses, on health economic analyses and international clinical studies. All efforts combined will fast-track the implementation of this Dutch healthcare innovation. ATRO Medical is the first company worldwide to have solutions for both the inner and outer meniscus close to the clinical stage.

Thousands of patients suffering from chronic knee pain are waiting for these solutions. Their meniscus has been removed as a result of an earlier trauma and they have developed the so-called post-meniscectomy pain syndrome. Orthopedic surgeon and Chief Medical Officer Dr. Tony van Tienen explains, “I see many patients with chronic knee pain in my clinical practice. Most of them are too young for a total knee replacement. However, they should be able to go to work, go shopping or simply walk their dog without constantly being bothered by an aching knee. Our artificial meniscus aims to relieve that pain. Pain free mobility, that is what we strive for.”

ATRO Medical has already received several international recognitions for their thought-leading work like FDA breakthrough device designation, Eurostars funding and the Johnson & Johnson Quickfire award. In the next few years, the company will leverage these endorsements and funds to significantly expand their clinical evidence and achieve market registration. Together with partners like the Dutch Arthritis Foundation, the Orthopaedic Research Laboratory and international clinics such as the Sint Maartenskliniek, Mayo Clinic and Sporthopaedicum Berlin they are confident to succeed.

Original source: ATRO Medical

Related news items

Boosting the startup ecosystem in Nijmegen!

22 June 2023

TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.

read more

ATRO Medical closes a new financing round for the Trammpolin® meniscus prosthesis

17 December 2021 ATRO Medical announces the successful closure of a €1.9 million financing round to complete the AIR2 clinical study. read more

Survey of patients to address knee pain from removed meniscus

19 November 2021 Patients with persistent knee pain after meniscus removal can participate at three locations in the Netherlands in the AIR2 study by ATRO Medical, a spin-off of the Radboudumc and DSM. read more

ATRO Medical, Radboudumc and Samaplast develop new meniscus prosthesis Consortium receives EUROSTARS grant for innovative project

16 July 2020 An international consortium led by ATRO Medical, a spin-off of Radboudumc and DSM, will receive € 800,000 European funding for an innovation aimed at patients with knee osteoarthritis. These patients often suffer from cartilage wear due to a meniscus that no longer works properly. read more

ATRO Medical's meniscus prothesis receives FDA Breakthrough Designation

22 January 2020 The Trammpolin meniscus is an implant that aims at reducing knee pain and improve mobility. read more